Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Development of population and Bayesian models for applied use in patients receiving cefepime

View ORCID ProfileJiajun Liu, View ORCID ProfileMichael Neely, Jeffrey Lipman, Fekade Sime, Jason Roberts, Patrick J Kiel, View ORCID ProfileSean N. Avedissian, View ORCID ProfileNathaniel J. Rhodes, View ORCID ProfileMarc H. Scheetz
doi: https://doi.org/10.1101/19009647
Jiajun Liu
1Midwestern University Chicago College of Pharmacy, Downers Grove, IL USA
2Northwestern Memorial Hospital, Chicago, IL USA
3Midwestern University Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiajun Liu
Michael Neely
4Children’s Hospital Los Angeles and University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Neely
Jeffrey Lipman
5UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia
6Royal Brisbane and Women’s Hospital, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fekade Sime
5UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia
7Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, University of Queensland, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Roberts
5UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia
6Royal Brisbane and Women’s Hospital, Brisbane, Australia
7Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, University of Queensland, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick J Kiel
8Indiana University Health, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean N. Avedissian
9Antiviral Pharmacology Laboratory, University of Nebraska Medical Center (UNMC) Center for Drug Discovery, UNMC, Omaha, NE USA
10University of Nebraska Medical Center, College of Pharmacy, Omaha, NE USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sean N. Avedissian
Nathaniel J. Rhodes
1Midwestern University Chicago College of Pharmacy, Downers Grove, IL USA
2Northwestern Memorial Hospital, Chicago, IL USA
3Midwestern University Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathaniel J. Rhodes
Marc H. Scheetz
1Midwestern University Chicago College of Pharmacy, Downers Grove, IL USA
2Northwestern Memorial Hospital, Chicago, IL USA
3Midwestern University Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc H. Scheetz
  • For correspondence: mschee@midwestern.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Understanding exposures of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients receiving cefepime treatment. Multiple physiologically relevant models were fit to pediatric and adult subject data. To evaluate the final model performance, a withheld group of twelve pediatric and two separate adult populations were assessed. Seventy subjects with a total of 604 cefepime concentrations were included in this study. All adults (n=34) on average weighed 82.7 kg and displayed a mean creatinine clearance (CrCL) of 106.7 mL/min. All pediatric subjects (n=36) had mean weight and CrCL of 16.0 kg and 195.64 mL/min, respectively. A covariate-adjusted two compartment model described the observed concentrations well (population model R2, 87.0%; Bayesian model R2, 96.5%). In the evaluation subsets, the model performed similarly well (population R2, 84.0%; Bayesian R2, 90.2%). The identified model serves well for population dosing and as a Bayesian prior for precision dosing.

Key points

  • A unified cefepime population pharmacokinetic model has been developed from adult and pediatric patients and evaluates well in independent populations.

  • When paired with real time beta-lactam assays, precision dosing approach will optimize drug exposure and improve clinical outcomes.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was utilized to complete this work. It was completed as part of our normal duties.

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Yes

Footnotes

  • Financial disclosure: None

Data Availability

Data are from primary manuscripts

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 18, 2019.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Development of population and Bayesian models for applied use in patients receiving cefepime
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Development of population and Bayesian models for applied use in patients receiving cefepime
Jiajun Liu, Michael Neely, Jeffrey Lipman, Fekade Sime, Jason Roberts, Patrick J Kiel, Sean N. Avedissian, Nathaniel J. Rhodes, Marc H. Scheetz
medRxiv 19009647; doi: https://doi.org/10.1101/19009647
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Development of population and Bayesian models for applied use in patients receiving cefepime
Jiajun Liu, Michael Neely, Jeffrey Lipman, Fekade Sime, Jason Roberts, Patrick J Kiel, Sean N. Avedissian, Nathaniel J. Rhodes, Marc H. Scheetz
medRxiv 19009647; doi: https://doi.org/10.1101/19009647

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)